Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

BACKGROUND: Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin (5-HT) and norepinephrine (noradrenaline) reuptake inhibitor approved for the treatment of major depressive disorder in adults. OBJECTIVE: The objective of this study was to evaluate the longer-term safety and toler...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Mago, Rajnish, Forero, Giovanna, Greenberg, William M., Gommoll, Carl, Chen, Changzheng
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2013
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3775192/
https://ncbi.nlm.nih.gov/pubmed/23999912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-013-0126-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky